ENTX
HealthcareEntera Bio Ltd.
$1.77
+$0.00 (+0.00%)
Jan 5, 2026
Price History (1Y)
Analysis
Entera Bio Ltd. is a healthcare company operating within the biotechnology industry. The company has a relatively small scale, with 20 employees and a market capitalization of $81.17 million. The company's financial health appears to be challenging, with significant losses reported in profitability metrics. The gross margin, operating margin, and profit margin are all at 0.0%, indicating no profit generation from sales or operations. Additionally, the net income is substantial at -$10,781,000, contributing to an EBITDA of -$10,790,000 and free cash flow of -$11,764,000. The company's returns on equity and assets are also negative at -99.4% and -53.8%, respectively. The company's valuation metrics suggest a significant discount in the market capitalization compared to its revenue. The price-to-sales ratio is 654.58, indicating that investors value the company based on this metric rather than traditional measures like earnings or book value.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Entera Bio Ltd.
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.
Visit website →Key Statistics
- Market Cap
- $81.17M
- P/E Ratio
- N/A
- 52-Week High
- $3.22
- 52-Week Low
- $1.50
- Avg Volume
- 185.06K
- Beta
- 1.78
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- Israel
- Employees
- 20